2019
P.026 Response to eculizumab in patients with myasthenia gravis recently treated with chronic intravenous immunoglobulin
Genge A, Jacob S, Murai H, Utsugisawa K, Nowak R, Wiendl H, Fujita K, O’Brien F, Howard J. P.026 Response to eculizumab in patients with myasthenia gravis recently treated with chronic intravenous immunoglobulin. Canadian Journal Of Neurological Sciences / Journal Canadien Des Sciences Neurologiques 2019, 46: s20-s21. DOI: 10.1017/cjn.2019.126.Peer-Reviewed Original ResearchIntravenous immunoglobulinMyasthenia gravisAnti-acetylcholine receptor antibody-positive refractoryRefractory myasthenia gravisOpen-label extensionPlacebo-controlled studyMeaningful clinical improvementExperienced exacerbationRescue therapyClinical improvementEighteen patientsMore patientsSubgroup analysisEculizumabPatientsPlaceboExacerbationRelevant improvementGravisPhase 3Status changesInterim dataImmunoglobulinPrevious reportsMeaningful responsesEarly intervention service for first episode psychosis in Modena, Northern Italy: The first hundred cases
Ferrara M, Tedeschini E, Baccari F, Musella V, Vacca F, Mazzi F, Ferri M, Srihari V, Starace F, Group F. Early intervention service for first episode psychosis in Modena, Northern Italy: The first hundred cases. Early Intervention In Psychiatry 2019, 13: 1011-1017. PMID: 30672134, DOI: 10.1111/eip.12788.Peer-Reviewed Original ResearchConceptsEarly intervention servicesClinical improvementMedian ageIntervention servicesCommunity mental health centerCommunity outpatient servicesPsychiatric hospital unitMeaningful clinical improvementFirst-episode psychosisModel of careNon-affective psychosisNation Outcome ScalesMental health centersHigher median ageEarly detection effortsRefinement of treatmentMain referralsPharmacological consultationYounger patientsUntreated psychosisOutcome ScaleGeneral practitionersEpisode psychosisHealth centersOutpatient services
2013
Rapid-Acting Glutamatergic Antidepressants: The Path to Ketamine and Beyond
Krystal JH, Sanacora G, Duman RS. Rapid-Acting Glutamatergic Antidepressants: The Path to Ketamine and Beyond. Biological Psychiatry 2013, 73: 1133-1141. PMID: 23726151, PMCID: PMC3671489, DOI: 10.1016/j.biopsych.2013.03.026.Peer-Reviewed Original ResearchConceptsAspartate glutamate receptor antagonist ketamineNovel antidepressant mechanismNovel treatment mechanismsSingle subanesthetic doseRapid-acting antidepressantsMeaningful clinical improvementGlutamatergic antidepressantsTraditional antidepressantsAntidepressant mechanismClinical improvementAntidepressant responseAntidepressant researchSubanesthetic doseKetamine studiesTherapeutic effectAntidepressantsKetamineTreatment mechanismsN-methylDose
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply